中国医院用药评价与分析2025，Vol.25Issue(11)：1328-1331,4.DOI:10.14009/j.issn.1672-2124.2025.11.010
117例棘阿米巴角膜炎患者的发病特点及药物治疗分析
Clinical Characteristics and Drug Treatment of 117 Cases with Acanthamoeba Keratitis
摘要
Abstract
OBJECTIVE:To probe into the clinical characteristics and drug treatment of Acanthamoeba keratitis.METHODS:Retrospective analysis was performed on the causes of onset and treatment regimens of 117 patients with Acanthamoeba keratitis admitted into the hospital from 2021 to 2024.The clinical characteristics and drug treatment were systematically summarized.RESULTS:Among 117 patients with Acanthamoeba keratitis,45 were males and 72 were females,with a male to female ratio of 1:1.6.There were 22 patients aged from＞10 to 20 years(18.80％)and 51 patients aged from＞40 to 70 years(43.59％).Totally 27 patients(23.08％)with contact lens wearing history,13 patients(11.11％)with corneal trauma history and 18 patients(15.38％)with surgical history.There were 40 cases of off-label drug use,metronidazole/voriconazole combined with polyhexamethylene-biguanide was the most common eye drops.A total of 116 patients(99.15％)achieved clinical recovery through drug treatment or combined with surgical treatment.CONCLUSIONS:After the diagnosis of Acanthamoeba keratitis,effective local anti-acanthamoeba drugs should be given early and sufficiently,and timely combined medication or surgical intervention measures should be given.In this paper,117 cases of Acanthamoeba keratitis were analyzed to provide reference for clinical treatment of Acanthamoeba keratitis.关键词
棘阿米巴/角膜炎/聚六亚甲基双胍/甲硝唑/伏立康唑Key words
Acanthamoeba/Keratitis/Polyhexamethylene-biguanide/Metronidazole/Voriconazole分类
医药卫生引用本文复制引用
吴宁莉,黎彦宏,郭未艳,吕娟,李亚美,王园姬..117例棘阿米巴角膜炎患者的发病特点及药物治疗分析[J].中国医院用药评价与分析,2025,25(11):1328-1331,4.基金项目
陕西省重点研发计划一般项目社会发展领域(No.2023-YBSF-070) （No.2023-YBSF-070）
2024年陕西省药学会医院药学高质量发展研究项目(No.2024-1-2-4) （No.2024-1-2-4）
